BR112021006620A2 - compostos de aminoácidos e métodos de uso - Google Patents
compostos de aminoácidos e métodos de usoInfo
- Publication number
- BR112021006620A2 BR112021006620A2 BR112021006620A BR112021006620A BR112021006620A2 BR 112021006620 A2 BR112021006620 A2 BR 112021006620A2 BR 112021006620 A BR112021006620 A BR 112021006620A BR 112021006620 A BR112021006620 A BR 112021006620A BR 112021006620 A2 BR112021006620 A2 BR 112021006620A2
- Authority
- BR
- Brazil
- Prior art keywords
- amino acid
- methods
- acid compounds
- compounds
- integrin
- Prior art date
Links
- -1 amino acid compounds Chemical class 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102000006495 integrins Human genes 0.000 abstract 2
- 108010044426 integrins Proteins 0.000 abstract 2
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 abstract 1
- 201000004071 non-specific interstitial pneumonia Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000005069 pulmonary fibrosis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Abstract
compostos de aminoácidos e métodos de uso. a presente invenção refere-se a compostos de fórmula (i), ou um sal deste, em que r1, g, l1, l2, l3 e y são como descritos no presente documento. os compostos de fórmula (i) e composições farmacêuticas dos mesmos são inibidores de um ou mais dentre, ou ambos, integrina avß1 e integrina avß6 que são úteis para o tratamento de fibrose, tal como esteato-hepatite não alcoólica (nash), fibrose pulmonar idiopática (iff) e pneumonia intersticial não específica (nsip). (i)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862742901P | 2018-10-08 | 2018-10-08 | |
| PCT/US2019/055252 WO2020076862A1 (en) | 2018-10-08 | 2019-10-08 | Amino acid compounds and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021006620A2 true BR112021006620A2 (pt) | 2021-07-06 |
Family
ID=70051340
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021006620A BR112021006620A2 (pt) | 2018-10-08 | 2019-10-08 | compostos de aminoácidos e métodos de uso |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US11180494B2 (pt) |
| EP (1) | EP3863711A4 (pt) |
| JP (1) | JP2022508657A (pt) |
| KR (1) | KR20210101205A (pt) |
| CN (1) | CN113195053A (pt) |
| AU (1) | AU2019358041A1 (pt) |
| BR (1) | BR112021006620A2 (pt) |
| CA (1) | CA3115643A1 (pt) |
| CL (2) | CL2021000863A1 (pt) |
| CO (1) | CO2021004279A2 (pt) |
| CR (1) | CR20210224A (pt) |
| CU (1) | CU24690B1 (pt) |
| DO (1) | DOP2021000054A (pt) |
| EA (1) | EA202190967A1 (pt) |
| EC (1) | ECSP21032717A (pt) |
| IL (1) | IL282026A (pt) |
| JO (1) | JOP20210056A1 (pt) |
| MX (1) | MX2021004015A (pt) |
| PE (1) | PE20211463A1 (pt) |
| PH (1) | PH12021550784A1 (pt) |
| SG (1) | SG11202103283RA (pt) |
| TW (1) | TW202028179A (pt) |
| WO (1) | WO2020076862A1 (pt) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201823208A (zh) | 2016-09-07 | 2018-07-01 | 美商普萊恩醫療公司 | N－醯基胺基酸化合物及其使用方法 |
| US10696672B2 (en) | 2016-12-23 | 2020-06-30 | Pliant Therapeutics, Inc. | Amino acid compounds and methods of use |
| US11046685B2 (en) | 2017-02-28 | 2021-06-29 | Morphic Therapeutic, Inc. | Inhibitors of (α-v)(β-6) integrin |
| US20180244648A1 (en) | 2017-02-28 | 2018-08-30 | Lazuli, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| WO2019173653A1 (en) | 2018-03-07 | 2019-09-12 | Pliant Therapeutics, Inc. | Amino acid compounds and methods of use |
| EA202190134A1 (ru) | 2018-06-27 | 2021-03-26 | Плайэнт Терапьютикс, Инк. | Соединения аминокислот с неразветвленными линкерами и способы их применения |
| CR20210109A (es) | 2018-08-29 | 2021-06-24 | Morphic Therapeutic Inc | INHIBICIÓN DE LA INTEGRINA av ß6 |
| TW202028179A (zh) | 2018-10-08 | 2020-08-01 | 美商普萊恩醫療公司 | 胺基酸化合物及使用方法 |
| CA3136745A1 (en) | 2019-04-08 | 2020-10-15 | Pliant Therapeutics, Inc. | Dosage forms and regimens for amino acid compounds |
| GB202010626D0 (en) * | 2020-07-10 | 2020-08-26 | Univ Nottingham | Compound |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6048861A (en) * | 1997-12-17 | 2000-04-11 | Merck & Co., Inc. | Integrin receptor antagonists |
| AR067329A1 (es) | 2007-06-13 | 2009-10-07 | Bristol Myers Squibb Co | Analogos dipeptidos como inhibidores del factor de coagulacion |
| US20120289481A1 (en) * | 2011-05-13 | 2012-11-15 | O'neil Jennifer | Compositions and methods for treating cancer |
| WO2015048819A1 (en) | 2013-09-30 | 2015-04-02 | The Regents Of The University Of California | Anti-alphavbeta1 integrin compounds and methods |
| GB201417011D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| CA2981371A1 (en) | 2015-03-10 | 2016-09-15 | The Regents Of The University Of California | Anti-alphavbeta1 integrin inhibitors and methods of use |
| WO2016153054A1 (ja) | 2015-03-25 | 2016-09-29 | 富士フイルム株式会社 | 新規な含窒素化合物またはその塩の製造方法およびそれらの製造中間体 |
| WO2018009501A1 (en) | 2016-07-05 | 2018-01-11 | The Rockefeller University | Tetrahydronaphthyridinepentanamide integrin antagonists |
| TW201823208A (zh) | 2016-09-07 | 2018-07-01 | 美商普萊恩醫療公司 | N－醯基胺基酸化合物及其使用方法 |
| EP3538526B1 (en) | 2016-11-08 | 2024-04-10 | Bristol-Myers Squibb Company | Cyclobutane- and azetidine-containing mono and spirocyclic compounds as alpha v integrin inhibitors |
| US10696672B2 (en) | 2016-12-23 | 2020-06-30 | Pliant Therapeutics, Inc. | Amino acid compounds and methods of use |
| US11046685B2 (en) * | 2017-02-28 | 2021-06-29 | Morphic Therapeutic, Inc. | Inhibitors of (α-v)(β-6) integrin |
| US20180244648A1 (en) | 2017-02-28 | 2018-08-30 | Lazuli, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| WO2019173653A1 (en) | 2018-03-07 | 2019-09-12 | Pliant Therapeutics, Inc. | Amino acid compounds and methods of use |
| TWI741268B (zh) | 2018-03-15 | 2021-10-01 | 美商輝瑞股份有限公司 | 干擾素基因刺激劑（ｓｔｉｎｇ）的環戊烷為主體之調節劑 |
| EA202190134A1 (ru) | 2018-06-27 | 2021-03-26 | Плайэнт Терапьютикс, Инк. | Соединения аминокислот с неразветвленными линкерами и способы их применения |
| CR20210109A (es) | 2018-08-29 | 2021-06-24 | Morphic Therapeutic Inc | INHIBICIÓN DE LA INTEGRINA av ß6 |
| WO2020047208A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| EP3843728A4 (en) | 2018-08-29 | 2022-05-25 | Morphic Therapeutic, Inc. | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN |
| TW202028179A (zh) | 2018-10-08 | 2020-08-01 | 美商普萊恩醫療公司 | 胺基酸化合物及使用方法 |
| CA3136745A1 (en) | 2019-04-08 | 2020-10-15 | Pliant Therapeutics, Inc. | Dosage forms and regimens for amino acid compounds |
| EP4146264A1 (en) | 2020-05-07 | 2023-03-15 | Pliant Therapeutics, Inc. | Treatment of respiratory diseases with amino acid compounds |
-
2019
- 2019-10-07 TW TW108136254A patent/TW202028179A/zh unknown
- 2019-10-08 KR KR1020217013781A patent/KR20210101205A/ko unknown
- 2019-10-08 PE PE2021000461A patent/PE20211463A1/es unknown
- 2019-10-08 CN CN201980066146.7A patent/CN113195053A/zh active Pending
- 2019-10-08 BR BR112021006620A patent/BR112021006620A2/pt unknown
- 2019-10-08 CA CA3115643A patent/CA3115643A1/en active Pending
- 2019-10-08 EP EP19870448.8A patent/EP3863711A4/en active Pending
- 2019-10-08 CR CR20210224A patent/CR20210224A/es unknown
- 2019-10-08 SG SG11202103283RA patent/SG11202103283RA/en unknown
- 2019-10-08 WO PCT/US2019/055252 patent/WO2020076862A1/en active Application Filing
- 2019-10-08 AU AU2019358041A patent/AU2019358041A1/en active Pending
- 2019-10-08 JO JOP/2021/0056A patent/JOP20210056A1/ar unknown
- 2019-10-08 JP JP2021544112A patent/JP2022508657A/ja active Pending
- 2019-10-08 US US16/596,649 patent/US11180494B2/en active Active
- 2019-10-08 EA EA202190967A patent/EA202190967A1/ru unknown
- 2019-10-08 CU CU2021000027A patent/CU24690B1/es unknown
- 2019-10-08 MX MX2021004015A patent/MX2021004015A/es unknown
-
2021
- 2021-03-30 DO DO2021000054A patent/DOP2021000054A/es unknown
- 2021-04-04 IL IL282026A patent/IL282026A/en unknown
- 2021-04-07 CL CL2021000863A patent/CL2021000863A1/es unknown
- 2021-04-07 CO CONC2021/0004279A patent/CO2021004279A2/es unknown
- 2021-04-08 PH PH12021550784A patent/PH12021550784A1/en unknown
- 2021-05-07 EC ECSENADI202132717A patent/ECSP21032717A/es unknown
- 2021-10-18 US US17/504,384 patent/US11952376B2/en active Active
-
2023
- 2023-05-08 CL CL2023001331A patent/CL2023001331A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020076862A1 (en) | 2020-04-16 |
| ECSP21032717A (es) | 2021-06-30 |
| EP3863711A1 (en) | 2021-08-18 |
| TW202028179A (zh) | 2020-08-01 |
| US11952376B2 (en) | 2024-04-09 |
| SG11202103283RA (en) | 2021-04-29 |
| AU2019358041A1 (en) | 2021-05-20 |
| JP2022508657A (ja) | 2022-01-19 |
| CO2021004279A2 (es) | 2021-04-30 |
| PE20211463A1 (es) | 2021-08-05 |
| CR20210224A (es) | 2021-06-08 |
| MX2021004015A (es) | 2021-06-23 |
| CN113195053A (zh) | 2021-07-30 |
| CA3115643A1 (en) | 2020-04-16 |
| EA202190967A1 (ru) | 2021-09-17 |
| US20200109141A1 (en) | 2020-04-09 |
| CU20210027A7 (es) | 2021-11-04 |
| CU24690B1 (es) | 2023-12-07 |
| US20220144829A1 (en) | 2022-05-12 |
| CL2021000863A1 (es) | 2021-09-10 |
| PH12021550784A1 (en) | 2021-10-25 |
| JOP20210056A1 (ar) | 2021-03-24 |
| DOP2021000054A (es) | 2021-08-31 |
| US11180494B2 (en) | 2021-11-23 |
| KR20210101205A (ko) | 2021-08-18 |
| IL282026A (en) | 2021-05-31 |
| CL2023001331A1 (es) | 2023-10-20 |
| EP3863711A4 (en) | 2022-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021006620A2 (pt) | compostos de aminoácidos e métodos de uso | |
| ECSP20063227A (es) | Compuestos de aminoácidos y métodos de uso | |
| BR112018068278A2 (pt) | derivado de 3-desóxi e suas composições farmacêuticas | |
| CU20210001A7 (es) | Compuestos de aminoácido con ligadores no ramificados como inhibidores de la integrina y composiciones farmacéuticas que los comprenden | |
| BR112019018648A2 (pt) | Inibidores de jak contendo uma amida heterocíclica com 4 membros | |
| BR112013032711A2 (pt) | composições farmacêuticas compreendendo sulbactam e inibidor de beta-lactamase | |
| BR112015022462A8 (pt) | inibidores de ido, composição farmacêutica, método de inibição de atividade de indolamina 2,3-dioxigenase e uso dos referidos inibidores | |
| BR112016028642A2 (pt) | composto, composição farmacêutica, método de tratamento de uma doença ou condição, método de inibição da atividade de um polipeptídeo de fosfatidilinositol 3-quinase, método de inibição de reações imunes ou crescimento excessivo ou destrutivo ou de proliferação de células cancerosas, kit, e, uso de um composto, de um sal, de um isômero ou de uma mistura farmaceuticamente aceitável do mesmo. | |
| BR112014009087A2 (pt) | formulações de etanercept estabilizadas com xilitol | |
| BR112017012197A2 (pt) | composto, composição herbicida, mistura herbicida e método para controlar o crescimento de vegetação indesejada | |
| BR112013010310A2 (pt) | inibidores de acetil-coa carboxilase de lactama n1/n2 | |
| BR112018013033A2 (pt) | compostos de indolinonas e seu uso no tratamentod de doenças fibróticas | |
| EA201990388A1 (ru) | Пиперидиновые модуляторы рецепторов cxcr7 | |
| BR112017000246A2 (pt) | composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal | |
| BR112017028616A2 (pt) | acentuador de inibidores de homólogo de zeste 2 | |
| BR112015024109A2 (pt) | derivados de ureia e seu uso como inibidores de proteína de ligação de ácidos graxos (fabp) | |
| EA202091003A1 (ru) | Новые производные пиразолопирролопиримидиндиона в качестве ингибиторов p2x3 | |
| BR112018068213A2 (pt) | derivados indólicos e seu uso como inibidores de proteína quinase | |
| CO2020006789A2 (es) | Procedimiento para la preparación de (3s)-3-(4-cloro-3-{[(2s,3r)-2-(4-clorofenil)-4,4,4-trifluor-3-metilbutanoil]amino}fenil)-3-ácido ciclopropilpropanoico y su forma cristalina para uso como principio activo farmacéutico | |
| BR112021014640A8 (pt) | Sais de sulcardina | |
| EA202092110A1 (ru) | Аминокислотные соединения и способы применения | |
| BR112018014622A2 (pt) | ?composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos para tratar uma infecção por hiv e para prevenir uma infecção por hiv, e, uso de um composto ou sal? | |
| BR112017007167A2 (pt) | moduladores do regulador de condutância transmembranar de fibrose cística | |
| BR112018003827A2 (pt) | composto, composição farmacêutica, combinação, uso de um composto, e, método para tratamento de uma doença ou condição. | |
| WO2013115884A3 (en) | Pyridopyrimidinone inhibitors of viruses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B154 | Notification of filing of divisional application [chapter 15.50 patent gazette] |
Free format text: O PEDIDO FOI DIVIDIDO NO BR122023025996-3 PROTOCOLO 870230109034 EM 11/12/2023 12:13. |